FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of Age and Older with pNET and epNET By Ogkologos - April 18, 2025 678 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CABINET study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR SABR with Immunotherapy Significantly Improves Event-Free Survival in Patients with Newly... July 27, 2023 Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC... June 24, 2025 24-Year-Old Woman with Terminal Breast Cancer Dreams of Fairytale Wedding with... April 16, 2019 10 Ways to Provide Support During Breast Cancer Awareness Month September 27, 2019 Load more HOT NEWS Genetic discovery could guide treatment for aggressive childhood cancer FDA Approves Talazoparib with Enzalutamide for HRR Gene-Mutated Metastatic Castration-Resistant Prostate... FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer Drug Combination May Have Potential for Cancers with TP53 Mutations
